ARK Genomic Revolution ETF (ARKG)
|Ex-Dividend Date||Dec 29, 2021|
|Day's Range||33.01 - 34.64|
|Inception Date||Oct 31, 2014|
The fund is an actively-managed exchange-traded fund (ETF) that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution (Genomics Revolution Companies). It is non-diversified.
Top 10 Holdings47.31% of assets
|CRISPR Therapeutics AG||CRSP||4.84%|
|Dec 29, 2021||$0.38239||Dec 31, 2021|
|Dec 29, 2020||$0.79013||Dec 31, 2020|
|Dec 27, 2019||$1.05395||Dec 31, 2019|
|Dec 27, 2018||$0.46634||Dec 31, 2018|
|Dec 27, 2017||$0.32769000000000004||Dec 29, 2017|
Ultima Genomics has claimed that its first instrument, the UG100, will sequence a human genome for under $100. The news surprised and perhaps delighted the life sciences community, as the price to seque...
With a targeted disruptive innovation biotechnology-related exchange traded fund strategy, investors can focus on companies driving change in targeted therapeutics, bioinformatics, CRISPR technology, an...
Thanks to DNA sequencing and the genomic revolution, we could be on the cusp of a brand-new era of healthcare solutions that could extend and enhance the quality of human life. Several key biotech compa...
Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves?
In the healthcare space, it's often said that an ounce of prevention is worth a pound of cure, and that's undeniably true when it comes to cancer prevention and treatment. A clear avenue for bolstering ...
Investors should keep an eye on innovative platforms-related exchange traded funds to capture tomorrow's growth ideas today. In the recent webcast, Refining Your Innovation Exposure: How to Access Tomor...
ARK's research identifies five innovation platforms that are evolving simultaneously, transforming the world around us. These platforms are Artificial Intelligence (AI), Blockchain Technology, Energy St...
The ARK CEO remains steadfast in her belief that her exchange-traded funds will outperform again.
Genomics has long been one of the more tech-centric corners of the healthcare space, and that remains the case today. That's a strong indication that disruptive technologies often intersect with and dep...
Disruptive technology-related exchange traded funds rallied on Tuesday as U.S. markets turned risk-on, following positive updates on Russia and Ukraine's negotiations. Among the best-performing non-leve...
Healthcare innovation equities are languishing, but it could time for one of the most well-known names in the group to turn around, and that could be constructive for select exchange traded funds, inclu...
While disruptive innovation strategies may experience short-term volatility, ARK's research shows that maintaining a long-term investment time horizon is critical for investors searching for potential r...
With biotechnology stocks, particularly those in mid- and small-cap territory, heavily out of favor at the moment, it's not surprising that some investors are ignoring genomics assets. That sentiment be...
Every night, an email comes out from Ark Investment Management highlighting the stocks that were bought or sold by the firm's ETFs. In recent months, the emails have been known to cause certain stocks t...
Experienced healthcare and biotechnology investors know that January brings the arrival of the widely followed JPMorgan healthcare conference. This year, it's taking place in virtual fashion, but that's...
Clustered regularly interspaced short palindromic repeats, colloquially known as CRISPR, is one of the bedrocks of the genomics investment thesis, and it could be poised for big things in 2022. If that'...